Jazz Pharma Ireland Ltd v. Qilu Pharmaceutical Hainan Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland) and Pharma Mar, S.A. (Spain)
  • Defendant: Qilu Pharmaceutical (Hainan) Co., Ltd. (China) and Qilu Pharma, Inc. (Pennsylvania)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Name: Jazz Pharmaceuticals Ireland Limited v. Qilu Pharmaceutical (Hainan) Co., Ltd.
• Case Identification: 1:26-cv-07840, D.N.J., 06/26/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Qilu Pharma, Inc. has an established place of business and employees in the state. For Defendant Qilu Pharmaceutical (Hainan) Co., Ltd., a foreign corporation, venue is alleged to be proper in any judicial district. Additionally, Plaintiffs allege both defendants have previously submitted to the jurisdiction of this Court in other matters.
• Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the cancer drug Zepzelca® (lurbinectedin) constitutes an act of infringement of three U.S. patents covering specific methods for treating small cell lung cancer (SCLC).
• Technical Context: The technology concerns specific clinical protocols for administering the chemotherapy drug lurbinectedin to treat metastatic SCLC, focusing on dose-reduction regimens to manage severe, life-threatening toxicities such as hepatotoxicity, neutropenia, and thrombocytopenia.
• Key Procedural History: This is a Hatch-Waxman action filed under 35 U.S.C. § 271(e)(2), triggered by Defendants' submission of ANDA No. 221419 seeking to market a generic version of lurbinectedin. The patents-in-suit are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book) for Zepzelca®. The complaint was filed within 45 days of Plaintiffs' receipt of Defendants' notice letter dated May 13, 2026, which included a Paragraph IV certification challenging the patents.

Case Timeline

Date	Event
2019-11-21	Earliest Priority Date for '806, '890, and '490 Patents
2020-06-15	FDA grants accelerated approval for Zepzelca® (lurbinectedin)
2025-06-10	U.S. Patent No. 12,324,806 ('806 Patent) Issues
2025-10-02	FDA approves Zepzelca® in combination therapy
2025-10-07	U.S. Patent No. 12,433,890 ('890 Patent) Issues
2025-10-14	U.S. Patent No. 12,440,490 ('490 Patent) Issues
2026-05-13	Defendants send Qilu Notice Letter to Plaintiffs
2026-06-26	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,324,806 - Method of Treating SCLC and Managing Hepatotoxicity

• Patent Identification: U.S. Patent No. 12,324,806, "Method of Treating SCLC and Managing Hepatotoxicity," issued June 10, 2025. Compl. ¶27

The Invention Explained

• Problem Addressed: The patent addresses the challenge of treating patients with metastatic small cell lung cancer (SCLC) whose disease has progressed after initial platinum-based chemotherapy. While the drug lurbinectedin is an effective treatment for this population, it can cause severe hepatotoxicity (liver toxicity), which may force discontinuation of the therapy. '806 Patent, col. 2:1-13 '806 Patent, col. 8:20-29
• The Patented Solution: The patent claims a specific method for managing this toxicity. The method involves administering a standard 3.2 mg/m² dose of lurbinectedin. If a patient subsequently experiences a severe (Grade ≥3) hepatotoxic event, the treatment protocol calls for administering a reduced dose of 2.6 mg/m² in the next cycle, provided the patient's blood counts and liver function have recovered to safe levels. '806 Patent, abstract '806 Patent, col. 4:1-12 This dose-adjustment strategy allows for continued treatment while mitigating a dangerous side effect.
• Technical Importance: This specific dosing regimen provides a clinically-tested protocol to keep patients on a life-extending therapy that might otherwise be stopped due to unmanageable toxicity. '806 Patent, col. 15:52-66

Key Claims at a Glance

• The complaint asserts infringement of at least Claim 1. Compl. ¶¶55-56
• Independent Claim 1 of the '806 Patent requires:
  • A method of treating metastatic SCLC in a patient with disease progression after platinum-based chemotherapy.
  • Administering a reduced dose of 2.6 mg/m² of lurbinectedin within 35 days of receiving an initial 3.2 mg/m² dose.
  • The patient must have previously experienced ≥ Grade 3 hepatotoxicity after the 3.2 mg/m² dose.
  • At the time of the reduced dose administration, the patient must have: (a) metastatic SCLC, (b) a platelet count of at least 100,000/mm³, (c) an absolute neutrophil count of at least 1500 cells/mm³, and (d) ≤ Grade 1 hepatotoxicity.
• The complaint reserves the right to assert infringement of other claims of the patent. Compl. ¶53

U.S. Patent No. 12,433,890 - Method of Treating SCLC and Managing Neutropenia

• Patent Identification: U.S. Patent No. 12,433,890, "Method of Treating SCLC and Managing Neutropenia," issued October 7, 2025. Compl. ¶30

The Invention Explained

• Problem Addressed: This patent addresses a different but equally serious toxicity associated with lurbinectedin treatment: neutropenia, a condition characterized by an abnormally low count of neutrophils (a type of white blood cell). Severe (Grade 4) neutropenia or febrile neutropenia can lead to life-threatening infections and treatment cessation. '890 Patent, col. 4:13-20 '890 Patent, col. 8:20-29
• The Patented Solution: The invention provides a method analogous to that of the '806 Patent, but tailored for neutropenia. If a patient on a 3.2 mg/m² dose of lurbinectedin experiences Grade 4 neutropenia or any grade of febrile neutropenia, the patent claims a method of administering a subsequent, reduced dose of 2.6 mg/m² after the patient's blood counts have recovered. '890 Patent, abstract '890 Patent, col. 4:13-30
• Technical Importance: The claimed method provides a specific, proactive strategy to manage a common and dangerous hematological side effect, thereby improving the safety profile of lurbinectedin and allowing for continued therapy in responsive patients. '890 Patent, col. 15:52-66

Key Claims at a Glance

• The complaint asserts infringement of at least Claim 1. Compl. ¶¶70-71
• Independent Claim 1 of the '890 Patent requires:
  • A method of treating metastatic SCLC in a patient with disease progression after platinum-based chemotherapy.
  • Administering a reduced dose of 2.6 mg/m² of lurbinectedin within 35 days of receiving an initial 3.2 mg/m² dose.
  • The patient must have previously experienced Grade 4 neutropenia or any grade febrile neutropenia after the 3.2 mg/m² dose.
  • At the time of the reduced dose administration, the patient must have: (a) metastatic SCLC, (b) a platelet count of at least 100,000/mm³, and (c) an absolute neutrophil count of at least 1500 cells/mm³.
• The complaint reserves the right to assert infringement of other claims of the patent. Compl. ¶68

U.S. Patent No. 12,440,490 - Method of Treating SCLC and Managing Thrombocytopenia

• Patent Identification: U.S. Patent No. 12,440,490, "Method of Treating SCLC and Managing Thrombocytopenia," issued October 14, 2025. Compl. ¶33
• Technology Synopsis: This patent addresses lurbinectedin-induced thrombocytopenia, a condition of dangerously low platelet counts. The patent claims a method for treating SCLC patients wherein a patient who experiences Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia after a 3.2 mg/m² dose is subsequently treated with a reduced 2.6 mg/m² dose, contingent on the patient's blood counts recovering to specified levels. '490 Patent, abstract Compl. ¶34 Compl. ¶85
• Asserted Claims: The complaint asserts infringement of at least Claim 1. Compl. ¶¶85-86
• Accused Features: The complaint alleges that the proposed product labeling for Qilu's generic lurbinectedin will instruct medical professionals to implement the specific dose reduction from 3.2 mg/m² to 2.6 mg/m² for patients who experience the claimed levels of thrombocytopenia. Compl. ¶¶87-88

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Defendants' generic lurbinectedin for injection, 4 mg/vial, for which they seek FDA approval via Abbreviated New Drug Application (ANDA) No. 221419. Compl. ¶¶9-10 Compl. ¶38 The complaint refers to this as "Qilu's Generic Product." Compl. ¶38
• Functionality and Market Context:
  • The infringement allegation is not directed at the chemical composition of the drug itself, but is a "method of use" claim triggered by the filing of the ANDA. The act of infringement is the submission of the ANDA seeking approval to market the drug for an indication claimed in the patents before their expiration. Compl. ¶53
  • The complaint alleges that the proposed product labeling for Qilu's Generic Product will serve as instructions for healthcare providers. These instructions are alleged to direct the use of the drug for treating metastatic SCLC and, critically, to direct the specific dose reduction regimens (e.g., from 3.2 mg/m² to 2.6 mg/m²) upon the occurrence of specific adverse events, as claimed in the patents-in-suit. Compl. ¶57 Compl. ¶72 Compl. ¶87 The complaint includes a visual of the chemical structure for lurbinectedin, identifying the active pharmaceutical ingredient central to the dispute. Compl. ¶26

IV. Analysis of Infringement Allegations

The complaint's theory of infringement is that Defendants' submission of ANDA No. 221419, which includes a proposed product label, constitutes induced infringement under 35 U.S.C. § 271(e)(2)(A) because the label will instruct medical professionals to perform the methods claimed in the '806, '890, and '490 patents.

'806 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality (from Proposed Label)	Complaint Citation	Patent Citation
A method of treating metastatic small cell lung cancer (SCLC) in a patient with disease progression after platinum-based chemotherapy, said method comprising administering...	The proposed labeling for Qilu's Generic Product will allegedly direct its use for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy.	¶57	col. 109:1-5
...within 35 days of receiving a dose of 3.2 mg/m² of lurbinectedin by intravenous infusion as a monotherapy, a dose of 2.6 mg/m² lurbinectedin...	The proposed labeling will allegedly direct administering a reduced dose of 2.6 mg/m³ following a patient experiencing Grade ≥3 hepatotoxicity at the 3.2 mg/m² dose, and within 35 days of receiving that dose.	¶57	col. 109:6-12
...to a patient having at the time of the administration of the dose of 2.6 mg/m² of lurbinectedin: a) metastatic SCLC... b) a platelet count of at least 100,000/mm³; c) an absolute neutrophil count of at least 1500 cells/mm³; and d) ≤ Grade 1 hepatotoxicity;	The proposed labeling will allegedly direct that the reduced dose be administered when the patient has a platelet count of at least 100,000/mm³, an absolute neutrophil count of at least 1500 cells/mm³, and Grade ≤1 hepatotoxicity.	¶57	col. 109:13-21
...wherein the patient previously experienced ≥ Grade 3 hepatotoxicity subsequent to receiving the dose of 3.2 mg/m² of lurbinectedin.	The proposed labeling will allegedly identify Grade ≥3 hepatotoxicity as an adverse reaction to treatment with 3.2 mg/m² of lurbinectedin and direct administering a reduced dose as a consequence.	¶57	col. 109:22-25

'890 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality (from Proposed Label)	Complaint Citation	Patent Citation
A method of treating metastatic small cell lung cancer (SCLC) in a patient with disease progression after platinum-based chemotherapy, said method comprising administering...	The proposed labeling will allegedly direct its use for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy.	¶72	col. 110:1-5
...within 35 days of receiving a dose of 3.2 mg/m² of lurbinectedin... a dose of 2.6 mg/m² lurbinectedin...	The proposed labeling will allegedly direct administering a reduced dose of 2.6 mg/m³ following a patient experiencing Grade 4 neutropenia or any grade febrile neutropenia at the 3.2 mg/m² dose, and within 35 days of that dose.	¶72	col. 110:6-11
...to the patient having at the time of the administration of the dose of 2.6 mg/m² of lurbinectedin: a) metastatic SCLC... b) a platelet count of at least 100,000/mm³; and c) an absolute neutrophil count of at least 1500 cells/mm³;	The proposed labeling will allegedly direct that the reduced dose be administered when the patient has a platelet count of at least 100,000/mm³ and an absolute neutrophil count of at least 1500 cells/mm³.	¶73	col. 110:12-18
...wherein the patient previously experienced Grade 4 neutropenia or any grade febrile neutropenia subsequent to receiving the dose of 3.2 mg/m² of lurbinectedin.	The proposed labeling will allegedly identify Grade 4 neutropenia and febrile neutropenia as adverse reactions to treatment with 3.2 mg/m² of lurbinectedin and direct administering a reduced dose as a consequence.	¶72	col. 110:19-23

• Identified Points of Contention:
  • Inducement Standard: A central issue will be whether the specific language in the Defendants' proposed label meets the legal standard for inducement. The analysis will focus on whether the label's language actively encourages, recommends, or promotes the patented method, as opposed to merely informing physicians of a possible course of action. The complaint's allegation that the label will "direct" this use will be a key point of contention. Compl. ¶57 Compl. ¶72 Compl. ¶87
  • Scope and Specificity: The claims are highly specific, reciting precise dosage levels (3.2 mg/m² and 2.6 mg/m²) and clinical criteria (e.g., "≥ Grade 3 hepatotoxicity," "platelet count of at least 100,000/mm³"). The infringement analysis will hinge on whether the proposed label instructs adherence to every one of these specific limitations. Any ambiguity or difference between the label's text and the claim language could form the basis of a non-infringement defense.

V. Key Claim Terms for Construction

• The Term: "previously experienced ≥ Grade 3 hepatotoxicity" '806 Patent, Claim 1, "previously experienced Grade 4 neutropenia or any grade febrile neutropenia" '890 Patent, Claim 1, and "previously experienced Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia" '490 Patent, Claim 1
• Context and Importance: These terms define the specific adverse event that triggers the claimed dose-reduction method. The entire patented process is contingent upon a patient meeting these clinical criteria. The definition of what constitutes each grade of toxicity is therefore fundamental to determining the scope of the claims.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Narrower Interpretation: The specifications explicitly tie the grading of adverse events to a specific, dated standard: "The grade of adverse events, such as neutropenia, thrombocytopenia, hepatotoxicity and other adverse toxicities are as set forth in the current set of criteria set forth in the National Cancer Institute (NCI) CTCAE, version 4.0 (May 28, 2009)." '806 Patent, col. 8:29-34 '890 Patent, col. 8:20-25 '490 Patent, col. 8:20-25 This language may support a narrow construction limited to the definitions within that specific version of the CTCAE guidelines.
  • Evidence for a Broader Interpretation: A party might argue that a person of ordinary skill in the art would understand the reference to CTCAE v4.0 to encompass clinically equivalent definitions in later versions of the same standard, especially if those standards are universally adopted in clinical practice. The patents also provide specific clinical parameter definitions for some toxicities within the specification itself, such as defining Grade 3 thrombocytopenia as a platelet count less than 50,000/mm³ but greater than or equal to 25,000/mm³. '806 Patent, col. 3:30-33

VI. Other Allegations

• Indirect Infringement: The complaint is premised on induced infringement under 35 U.S.C. § 271(b). It alleges that Defendants, by filing an ANDA with a proposed label that will instruct physicians to use lurbinectedin in the patented manner, intend to cause infringement once the generic product is approved and marketed. Compl. ¶56 Compl. ¶71 Compl. ¶86 Knowledge of the patents is alleged based on their listing in the Orange Book and the filing of this lawsuit. Compl. ¶52 Compl. ¶67 Compl. ¶82
• Willful Infringement: The complaint alleges that Defendants' infringement will be willful. This allegation is based on Defendants' alleged knowledge of the patents-in-suit, as demonstrated by their Paragraph IV certification and the Orange Book listing, which predates the ANDA filing. Compl. ¶¶52, 62 The complaint further characterizes Defendants' positions on non-infringement and invalidity as being "devoid of an objective good faith basis," seeking a finding that the case is "exceptional" and warrants an award of enhanced damages and attorneys' fees. Compl. ¶63 Compl. ¶78 Compl. ¶93 Compl. Prayer for Relief ¶G

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of inducement: does the specific language in the Defendants' proposed product label constitute active encouragement to perform the patented methods, or does it merely provide information that leaves the ultimate treatment decision to the physician's independent medical judgment? The outcome may depend on whether the label is found to "direct" or simply "describe" the claimed dose-reduction regimens.
• A second key question will be one of literal infringement: will the court find that the instructions on the proposed label map precisely onto every specific numerical and clinical limitation of the asserted claims? The dispute will likely focus on whether the label requires administration of the exact 2.6 mg/m² dose only after a specified Grade of toxicity is observed and only after the patient's clinical parameters meet the claimed recovery thresholds.